A Novel Magnetic Nanoparticle Drug Carrier for Enhanced Cancer Chemotherapy

Xu Chao, Zhuoli Zhang, Lili Guo, Jingjing Zhu, Mingli Peng, Alphonsus J.M. Vermorken, Wim J.M. van de Ven, Chao Chen, Yali Cui*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Background: Magnetic nanoparticles (NPs) loaded with antitumor drugs in combination with an external magnetic field (EMF)-guided delivery can improve the efficacy of treatment and may decrease serious side effects. The purpose of this study was 1) to investigate application of PEG modified GMNPs (PGMNPs) as a drug carrier of the chemotherapy compound doxorubicin (DOX) in vitro; 2) to evaluate the therapeutic efficiency of DOX-conjugated PGMNPs (DOX-PGMNPs) using an EMF-guided delivery in vivo. Methods: First, DOX-PGMNPs were synthesized and the cytotoxicity of DOX-PGMNPs was assessed in vitro. Second, upon intravenous administration of DOX-PMGPNs to H22 hepatoma cell tumor-bearing mice, the DOX biodistribution in different organs (tissues) was measured. The antitumor activity was evaluated using different treatment strategies such as DOX-PMGPNs or DOX-PMGPNs with an EMF-guided delivery (DOX-PGMNPs-M). Results: The relative tumor volumes in DOX-PGMNPs-M, DOX-PGMNPs, and DOX groups were 5.46±1.48, 9.22±1.51, and 14.8±1.64, respectively (each p<0.05), following treatment for 33 days. The life span of tumor-bearing mice treated with DOX-PGMNPs-M, DOX-PGMNPs, and DOX were 74.8±9.95, 66.1±13.5, and 31.3±3.31 days, respectively (each p<0.05). Conclusion: This simple and adaptive nanoparticle design may accommodate chemotherapy for drug delivery optimization and in vivo drug-target definition in system biology profiling, increasing the margin of safety in treatment of cancers in the near future.

Original languageEnglish (US)
Article numbere40388
JournalPloS one
Issue number10
StatePublished - Oct 8 2012

ASJC Scopus subject areas

  • General


Dive into the research topics of 'A Novel Magnetic Nanoparticle Drug Carrier for Enhanced Cancer Chemotherapy'. Together they form a unique fingerprint.

Cite this